AI assistant
Tempest Therapeutics, Inc. — Director's Dealing 2017
Jun 24, 2017
34632_dirs_2017-06-23_82516bc3-9ca9-40f0-bf1d-cfd2117b06e1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2017-06-21
Reporting Person: GILLIS JONATHAN (Vice President Finance)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $14.27 | 2023-09-10 | Common Stock (10000) | Direct | |
| Stock Option (right to buy) | $10.09 | 2024-03-05 | Common Stock (10000) | Direct | |
| Stock Option (right to buy) | $42.10 | 2025-03-03 | Common Stock (7500) | Direct | |
| Stock Option (right to buy) | $6.96 | 2026-03-03 | Common Stock (4000) | Direct | |
| Stock Option (right to buy) | $1.64 | 2027-01-05 | Common Stock (1000) | Direct | |
| Stock Option (right to buy) | $1.49 | 2027-03-02 | Common Stock (15000) | Direct |
Footnotes
F1: The shares underlying this option vested as to 25% of the shares on September 10, 2014, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2: The shares underlying this option vested as to 25% of the shares on March 5, 2015, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F3: The shares underlying this option vested as to 25% of the shares on March 3, 2016, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F4: The shares underlying this option vested as to 25% of the shares on March 3, 2017, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F5: 12.5% of the shares underlying this option vested on April 5, 2017 and as to an additional 12.5% of the shares underlying this option shall vest at the end of each successive three month period thereafter until January 5, 2019.
F6: The shares underlying this option shall vest as to 25% of the shares on March 2, 2018, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.